Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bilateral acute anterior uveitis after alendronate.

Literature DB >> 12446386

Bilateral acute anterior uveitis after alendronate.

A R Malik¹, S H Campbell, N M G Toma.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Alendronate

Year: 2002 PMID： 12446386 PMCID： PMC1771397 DOI： 10.1136/bjo.86.12.1443

Source DB: PubMed Journal: Br J Ophthalmol ISSN： 0007-1161 Impact factor: 4.638

× No keyword cloud information.

5 in total

1. Ocular inflammation associated with alendronate therapy.

Authors: J N Mbekeani; T L Slamovits; B H Schwartz; H L Sauer
Journal: Arch Ophthalmol Date: 1999-06

2. Bisphosphonates and iritis.

Authors: E S Siris
Journal: Lancet Date: 1993-02-13 Impact factor: 79.321

3. Uveitis associated with pamidronate.

Authors: K Ghose; R Waterworth; P Trolove; J Highton
Journal: Aust N Z J Med Date: 1994-06

4. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors: U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal: N Engl J Med Date: 1995-11-30 Impact factor: 91.245

5. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Authors: G A Colditz; S E Hankinson; D J Hunter; W C Willett; J E Manson; M J Stampfer; C Hennekens; B Rosner; F E Speizer
Journal: N Engl J Med Date: 1995-06-15 Impact factor: 91.245

5 in total

11 in total

Review 1. Ocular adverse effects associated with systemic medications : recognition and management.

Authors: Ricardo M Santaella; Frederick W Fraunfelder
Journal: Drugs Date: 2007 Impact factor: 9.546

2. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study.

Authors: Mahyar Etminan; Farzin Forooghian; David Maberley
Journal: CMAJ Date: 2012-04-02 Impact factor: 8.262

3. Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England.

Authors: Beate Aurich-Barrera; Lynda Wilton; Scott Harris; Saad A W Shakir
Journal: Drug Saf Date: 2006 Impact factor: 5.606

10. Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia. A 13-year experience.

Authors: Abdulmoein E Al-Agha; Rahaf S Hayatalhazmi
Journal: Saudi Med J Date: 2015-11 Impact factor: 1.484

Bilateral acute anterior uveitis after alendronate.

1. Ocular inflammation associated with alendronate therapy.

2. Bisphosphonates and iritis.

3. Uveitis associated with pamidronate.

4. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

5. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Review 1. Ocular adverse effects associated with systemic medications : recognition and management.

2. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study.

3. Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England.

Review 4. Safety of long-term bisphosphonate therapy for the management of osteoporosis.

5. A case report: zoledronic acid-induced anterior uveitis.

6. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.

7. Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications.

8. Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer.

9. Drug-induced uveitis.

10. Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia. A 13-year experience.